Early

Coronavirus Vaccine Shows Promising Early Results in China

A vaccine developed in China appears to be safe and may protect people from the new coronavirus, researchers reported on Friday.

The early-stage trial, published in the Lancet, was conducted by researchers at several laboratories and included 108 participants aged 18 to 60. Those who received a single dose of the vaccine produced certain immune cells, called T cells, within two weeks. Antibodies needed for immunity peaked at 28 days after the inoculation.

“This is promising data, but it’s early data,” said Dr. Dan Barouch, director of vaccine research at Beth Israel Deaconess Medical Center in Boston, who was not involved in the work. “Over all, I would say this is good news.”

The trial is the first step in testing the vaccine and was intended mainly to verify its safety. Proof of its effectiveness will require trials in thousands, perhaps hundreds of thousands, more people.

A vaccine for

Read More

Moderna Coronavirus Vaccine Trial Shows Promising Early Results

The first coronavirus vaccine to be tested in people appears to be safe and able to stimulate an immune response against the infection, the manufacturer, Moderna, announced on Monday, offering a glint of hope to a world desperate for ways to stop the pandemic.

The preliminary findings, in the first eight people who each received two doses of the experimental vaccine, must now be repeated in far larger tests in hundreds and then thousands of people, to find out if the vaccine can work in the real world. Moderna’s technology, involving genetic material from the virus called mRNA, is relatively new and has yet to produce any approved vaccine.

The promising early news sent Moderna’s stock soaring by more than 25 percent on Monday afternoon and helped drive Wall Street to its best day in six weeks. Stocks were also lifted by statements from the Federal Reserve chair, Jerome H.

Read More

Arthritis Drug Did Not Help Seriously Ill Covid Patients, Early Data Shows

Doctors around the world, trying to save seriously ill coronavirus patients, have been dosing them with rheumatoid arthritis drugs that can squelch immune responses. The theory was that many were dying because their immune systems went into overdrive, creating a fatal storm that attacked their lungs.

But now, preliminary results on treatments with one of these drugs, sarilumab, marketed as Kevzara and made by Regeneron and Sanofi, indicate that it does not help patients who are hospitalized but not using ventilators.

The rush to treat patients with rheumatoid arthritis drugs began with a tiny study in China in February. It involved just 21 patients, all of whom were hospitalized with Covid-19. All of the patients received a drug made by Roche, tocilizumab, that is very similar to sarilumab. The doctors reported that the patients’ fevers disappeared within days and, the doctors wrote, that “all other symptoms improved remarkably.” They ended

Read More

Asthma Is Absent Among Top Covid-19 Risk Factors, Early Data Shows

Dr. Linda Rogers, a specialist in pulmonary medicine at the Mt. Sinai Health system, which is on the front line of Covid treatment, said one would assume that patients with underlying lung diseases would be “at risk of worse outcomes.” But she said that “asthma is underrepresented” in patients that are sick enough to seek treatment.

Her practice focuses on people with more serious cases of asthma, but she has been able to successfully manage many of her asthma patients through telemedicine. “These are patients who, just based on their asthma alone, are on steroids all the time. I’m just surprised some of them haven’t done worse.”

Still, the data analysis on the effects of asthma is in its infancy, and health experts cited an existing body of research that shows the flu and milder coronaviruses exacerbate asthma as worrisome indicators for those with Covid-19. Dr. Rogers said that she

Read More